American Society of Hematology

Figure 1.

Figure 1. Onset of common grade ≥3 adverse events (in >3% of all treated patients) over time.

Onset of common grade ≥3 adverse events (in >3% of all treated patients) over time.

This Feature Is Available To Subscribers Only

Sign In or Create an Account